All In Biotech

Drug Trial Radar · NCT05728658

The Study of ICP-248 in Patients With Mature B-cell Malignancies

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients With Mature B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

191

Planned (sponsor's estimate)

Start

Mar 9, 2023

Primary completion

Aug 30, 2025

Study completion Oct 30, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.

Conditions

  • Hematological Malignancies

Interventions

  • ICP-248Drug

    Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.

  • ICP-248Drug

    Eligible patients will receive ICP-248 orally as specified in the treatment arm.

  • ICP-248+OrelabrutinibDrug

    Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

  • ICP-248+OrelabrutinibDrug

    Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

  • ICP-248 +RituximabDrug

    Eligible patients will receive ICP-248 and Rituximab as specified in the treatment arm.

  • ICP-248+OrelabrutinibDrug

    Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

  • ICP-248+Orelabrutinib+RituximabDrug

    Eligible patients will receive ICP-248 and Orelabrutinib and Rituximab as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose and recommended Phase 2 doseTime frame: 5 years
  2. To investigate the incidence, nature and severity of adverse events (AE) according to NCI-CTCAE V5.0 or iwCLL2018 evaluation criteria.Time frame: 5 years
  3. To evaluate the investigator-assessed overall response rate (ORR) of ICP-248 monotherapy or combination therapy at the recommended phase II dose (RP2D) .Time frame: 5 years

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • The Central Hospital of Wuhan

    Wuhan, Hubei, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China · Recruiting

  • Shenyang Hospital Of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Shandong cancer hospital

    Jinan, Shandong, China · Recruiting

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Hematology Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.